DAI-NIPPON-PRINTING
31.8.2021 03:02:06 CEST | Business Wire | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) has developed a Reflect Array that flexibly reflects the millimetre waves used in fifth generation (5G) mobile communications systems to expand coverage area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005245/en/
Compared to general metal reflectors, the new product is capable of reflecting millimetre waves in a more targeted manner. As a result, there are fewer restrictions on installation, making it possible to improve the communications environment in locations where radio waves have been difficult to reach, such as those in the shadow of buildings. In addition, the new product boasts superior design features allowing it to respond to various installation environment considerations.
Background
The 24GHz and above radio waves used in the high-speed large-capacity communications of 5G are higher frequency milliwaves than those used in 4G, and maintain a larger information capacity. At the same time, they are characterized by strong straightness properties and short reach, leading to radio waves being blocked in areas such as in the shadow of buildings making it difficult to ensure communication quality. Also, when adding base stations and relay equipment to resolve this issue, new challenges emerge, such as large costs and the difficulty of securing installation space.
DNP has once again risen to the challenge, taken advantage of proprietary microfabrication technology, and by applying an original concept has successfully separated the Frequency Selection Reflection Layer that selectively reflects predetermined frequency bands while merely passing through other radio waves, and the Reflective Direction Control Layer, a special dielectric layer that decides the direction of incoming and reflected radio waves, to develop a Reflect Array that makes it easier to control for the characteristics of each layer. The newly developed product is cheaper than installing base stations and relay equipment, and does not require a power source. It can, therefore, be installed in a variety of location, which contributes to significant improvements in the 5G communications environment.
Features
- Can be installed in a variety of locations
Unlike metal reflectors that reflect radio waves directly as in a mirror, the newly developed product is a reflective array capable of the asymmetric reflection of specific frequency radio waves. It is possible to flexibly set the frequency band to be reflected, the incidence angle of the radio waves received from the base station, and the reflection angle to deliver the radio waves, along with the spread of the reflection waves. As a result, it is now possible to effectively deliver radio waves to locations where it was previously difficult to do so. As a power source is no longer needed the new product can also be used in locations where installation space is restricted.
- Effective designs based on original concepts
The new product is comprised of three layers: the Frequency Selective Surface Layer that selectively reflects predetermined frequency bands while merely passing through other radio waves, the Reflective Direction Control Layer that decides the direction of incoming and reflected radio waves, and a Design Cover Layer that not only protects these two layers, but also provides the durability required of construction materials along with high level design features that are conducive to various installation environment considerations.
- Effective improvement of radio wave conditions
We have made it is possible to pre-adjust the spread of the reflection waves in answer to the desire to deliver reflection waves over a broad area, or to gather those waves into specific devices.
- Reduces the impact on existing radio waves
Unlike metal reflectors that reflect all radio waves, the new product passes through all but target radio waves, reducing the impact on existing radio waves.
- Superior design features
It is possible to print various patterns on the surface of the Design Cover Layer, making it possible to add external designs, including interior, exterior and advertising signboards.
Usage Scene
Recently, we have seen more companies and organizations consider the adoption of 5G as a means of targeting the realization of smart cities and smart factories that exploit robots and the Internet of Things (IoT). Commercialization efforts are already underway. With the development of the Reflect Array, we anticipate the following installation instances in cases where the radio wave environment is expected to deteriorate due to obstacles, and aim to link these initiatives to the spread of 5G.
- Improvement of the communication environment behind radio wave shields in smart factories
- Improvement of mobile device usage environment indoors at business offices and educational sites
- Usage at exhibition spaces where layouts change with each event and radio wave shielding conditions alter
- Usage at stadiums and amusement facilities where area-specific information is delivered
- Applications leveraging design elements, such as urban buildings, walls and signboards that require harmony with the surrounding environment
Looking Ahead
DNP will work jointly with various communications-related companies, including communications carriers, to verify the functionality of the new product, aiming for commercialization from FY 2023.
The new product is a Passive type Reflect Array that fixes the reflection direction of the radio waves. We will engage in joint development of an Active type Reflect Array with multiple companies, and this research has been selected as a national project in FY2021.
About DNP
DNP is one of the world’s largest comprehensive printing companies, providing a diverse portfolio of products and services to about 20,000 corporate clients worldwide. Since we were founded in 1876, we have consistently innovated new products and processes, and have successfully integrated proprietary printing and information technologies to branch out into various fields, including packaging, decorative materials, display components, and electronic devices. DNP continues to take on the challenge of new business fields, including those related to the environment, energy, and life sciences. Our aim is to become a principal provider of solutions to a variety of problems by developing and combining new technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005245/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
